Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01519063 · ClinicalTrials.gov registry record · Phase 2

Naltrexone and Memantine Effects on Alcohol Drinking Behaviors

A Phase 2 study, sponsored by Yale University.

Completed
Registry status
Phase 2
Development phase
75
Enrollment target

NCT01519063: Completed Phase 2 study, sponsored by Yale University.

NCT01519063 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01519063, a Phase 2 study, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 2
Development phase
75 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the combined effects of the study medications naltrexone and memantine on alcohol drinking behaviors.

Primary Outcome

Number of drinks consumed during the lab session (Day 7) after taking study medication, ranging from 0-12.

Interventions

  • DRUG Naltrexone and memantine first
  • DRUG Naltrexone and Placebo first

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2012-01
Est. Completion 2017-05-01
Phase Phase 2
Yale University

1,492 total trials

What the finished NCT01519063 record still lists

NCT01519063 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).

The record links to 0 conditions, and to 2 interventions - of which Naltrexone and memantine first is the first listed.

NCT01519063 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01519063 about?

NCT01519063 is a clinical study titled "Naltrexone and Memantine Effects on Alcohol Drinking Behaviors". The purpose of this study is to evaluate the combined effects of the study medications naltrexone and memantine on alcohol drinking behaviors.

What is the current status of trial NCT01519063?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2012-01. Estimated completion is 2017-05-01.

What interventions are being tested in trial NCT01519063?

The interventions under investigation include: Naltrexone and memantine first (DRUG), Naltrexone and Placebo first (DRUG).

Who is sponsoring clinical trial NCT01519063?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01519063's enrollment target sits among peer trials

75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01519063, the US trial registry maintained by the National Library of Medicine. NCT01519063 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.